You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 5,705,388


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,705,388
Title: CETP Ribozymes
Abstract:A nucleic acid molecule which blocks synthesis and/or expression of mRNAs associated with initial development, progression or regression of vascular disease.
Inventor(s): Couture; Larry (Louisville, CO), Stinchcomb; Dan (Boulder, CO), McSwiggen; James (Boulder, CO), Bisgaier; Charles (Ann Arbor, MI), Pape; Michael (Ann Arbor, MI)
Assignee: Ribozyme Pharmaceuticals, Inc. (Boulder, CO) Warner-Lambert Company (Ann Arbor, MI)
Application Number:08/363,240
Patent Claims:1. An enzymatic RNA molecule which specifically cleaves RNA produced from the gene encoding cholesterol ester transfer protein (CETP).

2. The enzymatic RNA molecule of claim 1, wherein said RNA molecule is in a hammerhead motif.

3. The enzymatic RNA molecule of claim 5, wherein the binding arms of said enzymatic RNA molecule comprises sequences complementary to any of sequences defined as Seq ID Nos 2-258.

4. The enzymatic RNA molecule of claim 1, wherein said RNA molecule is in a hairpin, hepatitis Delta virus, group I intron, VS nucleic acid or RNaseP RNA motif.

5. The hairpin enzymatic RNA molecule of claim 4, wherein said hairpin RNA molecule comprises sequences complementary any of sequences defined as Seq ID Nos 1078-1125.

6. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule comprises at least one sugar modification.

7. The enzymatic RNA molecule of claim 1, wherein said RNA comprises between 12 and 100 bases complementary to the RNA of said region.

8. The enzymatic RNA molecule of claim 1, wherein said RNA molecule comprises between 14 and 24 bases complementary to the RNA of said region.

9. The Enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule comprises any of sequences shown as Seq ID Nos 259-515 and 1030-1077.

10. A mammalian cell including an enzymatic RNA molecule of claim 1 in vitro.

11. The mammalian cell of claim 10, wherein said cell is a human cell.

12. An expression vector comprising nucleic acid encoding the enzymatic RNA molecule of claim 1, in a manner which allows expression and/or delivery of that enzymatic RNA molecule within a mammalian cell in vitro.

13. A mammalian cell including the expression vector of claim 12 in vitro.

14. The mammalian cell of claim 13, wherein said cell is a human cell.

Details for Patent 5,705,388

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.